Vaxart Q2 net loss narrows to $16.5M; BARDA award up to $453M for COVID Phase 2b

Vaxart, Inc.

Net loss per share $0.09 vs $0.16 YoY; revenue $6.4M (from $1.4M) on BARDA contract.
Cash and investments $62.6M at June 30; received ~$64.7M BARDA payment post-quarter.
BARDA Project NextGen award up to $453M to support 10,000-subject Phase 2b COVID trial vs mRNA comparator.
Enrollment for Phase 2b expected in H2 2024 pending FDA alignment; cash runway into 2026.
Norovirus vaccine: in discussions with FDA on correlates of protection; evaluating Phase 2b/challenge study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.